Literature DB >> 24424039

Differential permeability of the blood-testis barrier during reinitiation of spermatogenesis in adult male rats.

Jenna T Haverfield1, Sarah J Meachem, Peter K Nicholls, Katarzyna E Rainczuk, Evan R Simpson, Peter G Stanton.   

Abstract

The blood-testis barrier (BTB) sequesters meiotic spermatocytes and differentiating spermatids away from the vascular environment. We aimed to assess whether meiosis and postmeiotic differentiation could occur when the BTB is permeable. Using a model of meiotic suppression and reinitiation, BTB function was assessed using permeability tracers of small, medium, and large (0.6-, 70-, and 150-kDa) sizes to emulate blood- and lymphatic-borne factors that could cross the BTB. Adult rats (n = 9/group) received the GnRH antagonist acyline (10 wk) to suppress gonadotropins, followed by testosterone (24cm Silastic implant), for 2, 4, 7, 10, 15, and 35 days. In acyline-suppressed testes, all tracers permeated the seminiferous epithelium. As spermatocytes up to diplotene stage XIII reappeared, both the 0.6- and 70-kDa tracers, but not 150 kDa, permeated around these cells. Intriguingly, the 0.6- and 70-kDa tracers were excluded from pachytene spermatocytes at stages VII and VIII but not in subsequent stages. The BTB became progressively impermeable to the 0.6- and 70-kDa tracers as stages IV-VII round spermatids reappeared in the epithelium. This coincided with the appearance of the tight junction protein, claudin-12, in Sertoli cells and at the BTB. We conclude that meiosis can occur when the BTB is permeable to factors up to 70 kDa during the reinitiation of spermatogenesis. Moreover, BTB closure corresponds with the presence of particular pachytene spermatocytes and round spermatids. This research has implications for understanding the effects of BTB dynamics in normal spermatogenesis and also potentially in states where spermatogenesis is suppressed, such as male hormonal contraception or infertility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24424039     DOI: 10.1210/en.2013-1878

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Effect of hormone modulations on donor-derived spermatogenesis or colonization after syngeneic and xenotransplantation in mice.

Authors:  G Shetty; Z Wu; T N A Lam; T T Phan; K E Orwig; M L Meistrich
Journal:  Andrology       Date:  2018-11-23       Impact factor: 3.842

2.  Highly Conserved Testicular Localization of Claudin-11 in Normal and Impaired Spermatogenesis.

Authors:  Angelika Stammler; Benjamin Udo Lüftner; Sabine Kliesch; Wolfgang Weidner; Martin Bergmann; Ralf Middendorff; Lutz Konrad
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

3.  Contemporaneous effects of diabetes mellitus and hypothyroidism on spermatogenesis and immunolocalization of Claudin-11 inside the seminiferous tubules of mice.

Authors:  Nazar Ali Korejo; Quanwei Wei; Kaizhi Zheng; Dagan Mao; Rashid Ali Korejo; Atta Hussain Shah; Fangxiong Shi
Journal:  BMC Dev Biol       Date:  2018-06-26       Impact factor: 1.978

4.  Claudin-11 and occludin are major contributors to Sertoli cell tight junction function, in vitro.

Authors:  Mark J McCabe; Caroline Fh Foo; Marcel E Dinger; Peter M Smooker; Peter G Stanton
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

5.  Perfluorooctanesulfonate (PFOS)-induced Sertoli cell injury through a disruption of F-actin and microtubule organization is mediated by Akt1/2.

Authors:  Ying Gao; Haiqi Chen; Xiang Xiao; Wing-Yee Lui; Will M Lee; Dolores D Mruk; C Yan Cheng
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

6.  Changes in Expression of Specific mRNA Transcripts after Single- or Re-Irradiation in Mouse Testes.

Authors:  Kenta Nagahori; Ning Qu; Miyuki Kuramasu; Yuki Ogawa; Daisuke Kiyoshima; Kaori Suyama; Shogo Hayashi; Kou Sakabe; Takayuki Yoshimoto; Masahiro Itoh
Journal:  Genes (Basel)       Date:  2022-01-15       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.